BridgeBio, First Korean Company to Join Global Pulmonary Fibrosis Research Consortium

Bridge Biotherapeutics announced on the 12th that it has joined the global lung fibrosis research organization Prognostic Lung Fibrosis Consortium (PROLIFIC) as the first domestic company.

Bridge Biotherapeutics CI. [Image provided by Bridge Biotherapeutics]

PROLIFIC is an international non-profit organization aimed at promoting scientific exploration and new drug development for lung fibrosis. Launched in 2020, it is based on the voluntary cooperation of member companies including global pharmaceutical companies leading the development of lung fibrosis treatments, hospitals, research institutes, and bio ventures. By sharing expertise, advanced technologies, and data on lung fibrotic diseases with high unmet medical needs, it develops personalized treatments for lung fibrosis patients.

Bridge Biotherapeutics has joined PROLIFIC as a new member and plans to collaborate and cooperate with global pharmaceutical companies and bio ventures leading innovative drug development in this field. Through this, it aims to further accelerate the development of BBT-877 (autotaxin inhibitor), currently in Phase 2 clinical trials. Additionally, based on research data of early-stage drug candidates in the preclinical phase, ▲BBT-301 (ion channel modulator) and ▲BBT-209 (GPCR19 agonist), the company plans to establish future clinical development strategies and advance its idiopathic pulmonary fibrosis pipeline.

Jung Su-jin, Vice President of Clinical Development at Bridge Biotherapeutics, said, "We are pleased to join the global research consortium in the field of fibrotic lung diseases, closely collaborate with global leaders in this field, enhance our understanding of the disease, and participate in global cooperation to explore new biomarkers." She added, "We hope that global solidarity beyond national borders will further activate new drug research and development cooperation in the field of fibrotic lung diseases."

Idiopathic pulmonary fibrosis is a fatal disease that can lead to death within 3 to 5 years without appropriate treatment. Since last year, Bridge Biotherapeutics has been focusing on this as a major strategic disease area and is progressing with development. BBT-877 has entered multinational Phase 2 clinical trials, and since the first patient dosing in April, more than 20 idiopathic pulmonary fibrosis patients have been enrolled and are currently receiving treatment.

This content was produced with the assistance of AI translation services.